ANIXA BIOSCIENCES, INC. Cost of Goods Sold (Deprecated 2018-01-31)
ANIXA BIOSCIENCES, INC. (ANIX) reported Cost of Goods Sold (Deprecated 2018-01-31) of $27.07 thousand for the 9-month period ending 2013-07-31, per its 10-Q/A filed 2013-09-20.
Discontinued › Expense Statement
us-gaap:CostOfGoodsSold · last filed 2013-09-20
- ANIXA BIOSCIENCES, INC. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2013-07-31 was $0.00, a 100.00% decline year-over-year.
- ANIXA BIOSCIENCES, INC. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2013-04-30 was $0.00, a 100.00% decline year-over-year.
- ANIXA BIOSCIENCES, INC. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2013-01-31 was $27.07K, a 3572.59% increase year-over-year.
- ANIXA BIOSCIENCES, INC. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2012-10-31 was $1.93K, a 222.45% increase year-over-year.
- ANIXA BIOSCIENCES, INC. cost of goods sold (deprecated 2018-01-31) for fiscal 2012 was $3.87K, a 88.64% decline from fiscal 2011.
- ANIXA BIOSCIENCES, INC. cost of goods sold (deprecated 2018-01-31) for fiscal 2011 was $34.08K, a 58.59% decline from fiscal 2010.
- ANIXA BIOSCIENCES, INC. cost of goods sold (deprecated 2018-01-31) for fiscal 2010 was $82.31K.
| Period end | Cost of Goods Sold (Deprecated 2018-01-31) 3 month | Cost of Goods Sold (Deprecated 2018-01-31) 6 month | Cost of Goods Sold (Deprecated 2018-01-31) 9 month | Cost of Goods Sold (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2013-07-31 | $0.00 derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2013-09-20 | $0.00 derived: sum of 2 quarters · filed 2013-09-20 | $27.07K 10-Q/A · filed 2013-09-20 | $28.99K derived: sum of 4 quarters · filed 2013-09-20 |
| 2013-04-30 | $0.00 derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2013-06-19 | $27.07K 10-Q/A · filed 2013-06-19 | $28.99K derived: sum of 3 quarters · filed 2013-06-19 | $29.71K derived: sum of 4 quarters · filed 2013-09-20 |
| 2013-01-31 | $27.07K 10-Q/A · filed 2013-03-25 | $28.99K derived: sum of 2 quarters · filed 2013-03-25 | $29.71K derived: sum of 3 quarters · filed 2013-09-20 | $30.20K derived: sum of 4 quarters · filed 2013-09-20 |
| 2012-10-31 | $1.93K derived: 10-K 12 month − 10-Q/A 9 month · filed 2013-01-29 | $2.64K derived: sum of 2 quarters · filed 2013-09-20 | $3.14K derived: sum of 3 quarters · filed 2013-09-20 | $3.87K 10-K · filed 2013-01-29 |
| 2012-07-31 | $714.00 10-Q/A · filed 2013-09-20 | $1.21K derived: sum of 2 quarters · filed 2013-09-20 | $1.95K 10-Q/A · filed 2013-09-20 | $2.54K derived: sum of 4 quarters · filed 2013-09-20 |
| 2012-04-30 | $497.00 10-Q/A · filed 2013-06-19 | $1.23K 10-Q/A · filed 2013-06-19 | $1.83K derived: sum of 3 quarters · filed 2013-06-19 | $5.46K derived: sum of 4 quarters · filed 2013-06-19 |
| 2012-01-31 | $737.00 10-Q/A · filed 2013-03-25 | $1.33K derived: sum of 2 quarters · filed 2013-03-25 | $4.96K derived: sum of 3 quarters · filed 2013-03-25 | $29.61K derived: sum of 4 quarters · filed 2013-03-25 |
| 2011-10-31 | $597.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-01-29 | $4.22K derived: sum of 2 quarters · filed 2013-01-29 | $28.88K derived: sum of 3 quarters · filed 2013-01-29 | $34.08K 10-K · filed 2013-01-29 |
| 2011-07-31 | $3.63K 10-Q · filed 2012-09-14 | $28.28K derived: sum of 2 quarters · filed 2012-09-14 | $33.48K 10-Q · filed 2012-09-14 | $40.74K derived: sum of 4 quarters · filed 2012-09-14 |
| 2011-04-30 | $24.65K 10-Q · filed 2012-06-14 | $29.86K 10-Q · filed 2012-06-14 | $37.11K derived: sum of 3 quarters · filed 2012-06-14 | $71.11K derived: sum of 4 quarters · filed 2012-06-14 |
| 2011-01-31 | $5.21K 10-Q · filed 2012-03-16 | $12.46K derived: sum of 2 quarters · filed 2012-03-16 | $46.46K derived: sum of 3 quarters · filed 2012-03-16 | |
| 2010-10-31 | $7.25K derived: 10-K 12 month − 10-Q/A 9 month · filed 2012-01-30 | $41.26K derived: sum of 2 quarters · filed 2012-01-30 | $82.31K 10-K · filed 2012-01-30 | |
| 2010-07-31 | $34.00K 10-Q/A · filed 2011-10-14 | $75.06K 10-Q/A · filed 2011-10-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 |